David Amsellem

“So, I guess my question here is, as you think about this product, can you give us a sense of where you think its share of the market could be in terms of, you know, percentage of oral olanzapine switches?”

“So on AD agitation, I know these are early days, but do you have a good read regarding how the drug is being used relative to reuptake inhibitors? Are you seeing usage in frontline or downstream of reuptake inhibitors that historically have been used off-label in AD agitation or maybe a mix of both?”

“First, just wanted to clarify, side, Nikhil. Are cases the same as prescriptions written? And if they're not, can you talk about how many of those cases that you referred to, a percentage of those cases are actually becoming active prescriptions?”

“First on Cenarimod, my understanding is that background Benlista is allowed in the trial. So wondering about the thought process there and is it stratified or the patient stratified for background Benlista?”

“So I had a question about your tau program with the data coming next year.”